NCT06146504

Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of an Anti-Fungal Supplement

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: CanXida · Industry
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This is a virtual, double-blind, two-arm, randomized, placebo-controlled clinical trial that will last 12 weeks. Participants will take the CanXida Remove Candida Cleansing Formula RMV or a placebo product daily and complete questionnaires at Baseline, Week 6, and Week 12. Candida microbiome testing will be conducted via stool sample at Baseline and Week 12. The participants will all be blinded to the name of the test brand.

Conditions

• Candida Systemic
• Candida Albicans Infection
• Candida Infection

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	CanXida Remove (Formula RMV)	Supplement composed of a 12 ingredient anti-fungal, anti-bacterial \& anti-parasite formula.
OTHER	Placebo	Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.

Timeline

• Start date: 2023-11-30
• Primary completion: 2024-06-28
• Completion: 2024-06-28
• First posted: 2023-11-24
• Last updated: 2024-08-22

Locations

1 site across 1 country: United States